Is Incyte Stock Outperforming the Nasdaq?

With a market cap of $18.7 billion, Wilmington, Delaware-based Incyte Corporation (INCY) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics across the United States, Europe, Canada, and Japan. Its marketed portfolio includes treatments for oncology, hematology, and immune-related diseases. 

Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and Incyte fits this criterion perfectly. The company also advances a robust clinical-stage pipeline through internal research and strategic collaborations.